BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...SIGLEC3) Complement 6 (C6) Complement component 1 q subcomponent (C1q) Complement receptor 5A (C5AR1) (C5AR) (CD88) I-kappa B kinase (IKK) Inhibitor of kappa light polypeptide gene enhancer in B cells kinase beta (IKKbeta) (IKBKB) (IKK2) (NRKBIKB) Macrophage...
BioCentury | Mar 13, 2019
Distillery Therapeutics

IKKβ inhibition for tendinopathy

...TARGET/MARKER/PATHWAY: Inhibitor of κ light polypeptide gene enhancer in B cells kinase β (IKKβ; IKBKB; IKK2...
...Feb. 27, 2019 doi:10.1126/scitranslmed.aav4319 CONTACT: Stavros Thomopoulos, Columbia University, New York, N.Y. email: sat2@columbia.edu Claire Quang Columbia University Inhibitor of kappa light polypeptide gene enhancer in B cells kinase beta (IKKbeta) (IKBKB) (IKK2) (NRKBIKB) Musculoskeletal...
BioCentury | Aug 16, 2018
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture studies suggest inhibiting IKK or its scaffold protein NEMO in combination with inhibition of MC-1 could help treat STK11-deficient lung cancer. In a human STK11-deficient lung cancer cell line, the...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Hepatic

INDICATION: Liver disease Mouse studies suggest inhibiting IKKα or its activator MAP3K14 could help treat liver disease. In a partial hepatectomy mouse model of liver injury, hepatocyte-specific knockout of MAP3K14 or IKKα increased hepatocyte proliferation...
BioCentury | Apr 13, 2018
Preclinical News

NCI identifies new lymphoma subtypes

A New England Journal of Medicine paper out of NIH's National Cancer Institute revealed new subtypes of diffuse large B cell lymphomas (DLBCL) that could lead to more targeted therapeutic strategies. The report adds to...
BioCentury | Apr 10, 2018
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture, and mouse studies suggest inhibiting IKKα could help treat KRAS-mutant lung adenocarcinoma. In patient samples, levels of IKKα were higher in tumors than in adjacent normal lung tissue....
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Nov 21, 2017
Preclinical News

New tool for degradation of endogenous proteins

In a study published in Cell , researchers at Medical Research Council Laboratory of Molecular Biology (MRC LMB) and colleagues describe a new protein degradation technique called Trim-Away that harnesses a naturally occurring ubiquitinating protein and...
BioCentury | Jul 31, 2017
Distillery Therapeutics

Endocrine / Metabolic

...TARGET/MARKER/PATHWAY: Inhibitor of κ light polypeptide gene enhancer in B cells kinase β (IKKβ; IKBKB; IKK2...
...Calif. email: skoliwad@diabetes.ucsf.edu Hongjiang Li University of California San Francisco University of Washington Colony-stimulating factor 1 receptor (CSF1R) (C-FMS) (CD115) Inhibitor of kappa light polypeptide gene enhancer in B cells kinase beta (IKKbeta) (IKBKB) (IKK2) (NRKBIKB)...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
Items per page:
1 - 10 of 57